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Mentor: Tammie Benzinger
The effect of statins, beta blockers, selective serotonin reuptake inhibitors (SSRIs), and 
other drug classes on Alzheimer’s pathology is not well characterized. The objective of 
this project was to investigate potential relationships between these drugs and certain 
measures reflective of Alzheimer’s pathology. Participants in ongoing studies on aging 
and dementia from the Knight Alzheimer Disease Research Center at Washington 
University were selected for this analysis. Medication data was self-reported for all 
participants, so a string matching algorithm in R was used to correct spellings and classify 
drugs into different categories (statins, beta blockers, etc). These participants (~13,000) 
have Aβ and tau PET imaging, CSF, structural MRI, and clinical dementia rating (CDR) 
measures. APOE4 status (APOE4 allele increases risk of Alzheimer’s disease), gender, and 
education levels were controlled for. Basic linear regressions and general linear models 
show that statins delay the onset of dementia associated with Alzheimer’s disease, but 
there is no evidence to suggest that statins slow the progression of Alzheimer’s pathology 
after onset. Additionally, no trend was found between beta blocker usage and Alzheimer’s 
onset or progression of pathology. Genotypic analysis to investigate rates of drug usage 
between APOE4 carriers and non-APOE4 carriers reveals that proton pump inhibitors 
(PPIs) are used at a significantly lower rate among APOE4 carriers (p = 0.00174), and 
SSRIs are used at a higher rate among APOE4 carriers (p = 0.08671). This uneven usage 
may serve as a basis for further exploration of the relationship between these drugs and 
Alzheimer’s disease.
